Daniel Wilkinson is a highly educated professional with an impressive record of academic and professional accomplishments. He holds a Doctor of Philosophy (PhD) in Biosensors from Imperial College London, an MRes degree in Chemical Biology of Health and Disease also from Imperial College London, and a 2.1 Honours degree in Nanotechnology from the University of Leeds. He has gained a wealth of experience during his professional career, holding positions such as Equity Research Analyst at Morgan Stanley, and Associate Director and Associate Analyst in Healthcare (Biotech) at Edison Investment Research. Daniel's academic expertise lies in biosensors and biotechnology, with a particular focus on diabetes. Moreover, he has also gained valuable research experience working as a Research Assistant at eTect, Electronic Biomarker Detection.